High Variability in Erythrocyte, Plasma and Whole Blood EPA and DHA Levels in Response to Supplementation

(1) Aim: the aim of this secondary analysis was to report the variability in response to n-3 long chain polyunsaturated fatty acids (LCPUFA) supplementation in erythrocytes, plasma and whole blood of a previously published dose response study. (2) Methods: a randomized, double-blind, placebo-controlled trial of parallel design was conducted, whereby pre-menopausal women were randomly assigned to consume 0, 0.35, 0.7 or 1 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA). Fasted blood samples were taken at baseline and after eight weeks intervention. Erythrocyte, plasma and whole blood fatty acids were extracted using the method of Lepage and Roy and analysed using gas chromatography. (3) Results: There were significant increases in EPA plus DHA levels in the 0.7 g and 1 g dose groups, with the highest increase with the 1 g dose notably: in erythrocytes (from 5.69% to 7.59%), plasma (from 2.94% to 5.48%) and in whole blood (from 3.81% to 6.03%). There was high variability in response to the supplement in erythrocytes, plasma and whole blood across the different doses. (4) Conclusion: there is high individual variability in n-3 LCPUFA levels in response to n-3 LCPUFA supplementation, which should be taken into account in clinical trials using n-3 LCPUFA supplements.

Download Full-text

Biomarkers of Docosahexaenoic Acid but Not Arachidonic Acid Reflect Dietary Intakes in Toddlers at Ages 1 and 2 Years Who Are Not Meeting Dietary Recommendations

Journal of Nutrition ◽

10.1093/jn/nxz280 ◽

2019 ◽

Vol 150 (3) ◽

pp. 518-525

Author(s):

Alejandra M Wiedeman ◽

Roger A Dyer ◽

Deanna McCarthy ◽

Karin Yurko-Mauro ◽

Sheila M Innis ◽

...

Keyword(s):

Fatty Acids ◽

Arachidonic Acid ◽

Controlled Trial ◽

Secondary Analysis ◽

Dietary Intakes ◽

Dietary Recommendations ◽

Double Blind ◽

Dietary Pufa ◽

Food Records ◽

Epa And Dha

ABSTRACT Background Long-chain n–6 and n–3 PUFAs are important for growth and development. However, little is known about requirements and current dietary intakes of these fatty acids in toddlers. Objectives This study assessed dietary intakes of n–6 and n–3 PUFAs and determined the relation to circulating PUFAs in toddlers at ages 1 and 2 y. Methods This is a secondary analysis of data from toddlers enrolled in a double-blind randomized controlled trial of arachidonic acid (ARA) and DHA supplementation between ages 1 and 2 y. Dietary intakes of fatty acids were estimated by 3-d food records, and fatty acid composition in plasma total phospholipids, red blood cell phosphatidylethanolamine (PE), and phosphatidylcholine (PC) were assessed by GC at baseline in all subjects (n = 110; mean age 1.12 y; 64% male) and in the control subjects at 2 y (n = 43). Results The dietary intakes of ARA, EPA, and DHA at age 1 y (baseline) were [mean (median)] 36.8 (30.0), 16.0 (0.00), and 31.1 (10.0) mg/d, respectively. Dietary intakes increased to 52.7 (45.0), 35.8 (0.00), and 64.8 (20.0) mg/d, respectively, at age 2 y (P < 0.05). The predominant dietary source of EPA and DHA was fish/seafood; eggs were an important source of ARA and DHA. Dietary DHA intakes were positively associated with plasma PE and PC DHA (P < 0.05). No relations between dietary ARA intakes and plasma PE and PC ARA (P > 0.05) were observed. Conclusions These findings suggest that most toddlers are not meeting the recommendation for dietary PUFA intakes and that higher dietary DHA intakes are reflected in plasma PE and PC DHA composition. Further work is required to investigate a biomarker for dietary ARA intake. This trial is registered at clinicaltrials.gov as NCT01263912.

Download Full-text

P4-158: Omega-3 Fatty Acids and Cognitive Performance in Coronary Artery Disease Patients: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial

Alzheimer s & Dementia ◽

10.1016/j.jalz.2016.06.2250 ◽

2016 ◽

Vol 12 ◽

pp. P1075-P1075

Author(s):

Nathan Herrmann ◽

Graham Mazereeuw ◽

Paul I. Oh ◽

David W.L. Ma ◽

Alexander Kiss ◽

...

Keyword(s):

Coronary Artery Disease ◽

Fatty Acids ◽

Coronary Artery ◽

Controlled Trial ◽

Secondary Analysis ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Artery Disease

Download Full-text

Faculty Opinions recommendation of Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1103835.559964 ◽

2008 ◽

Author(s):

Deborah Kim

Keyword(s):

Fatty Acids ◽

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Trial ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Effects of exergame training combined with omega-3 fatty acids on the elderly brain: a randomized double-blind placebo-controlled trial

BMC Geriatrics ◽

10.1186/s12877-019-1084-4 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 3

Author(s):

Alexandra Schättin ◽

Corinne Baier ◽

Domenique Mai ◽

Verena Klamroth-Marganska ◽

Isabelle Herter-Aeberli ◽

...

Keyword(s):

Fatty Acids ◽

Controlled Trial ◽

The Elderly ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol

Trials ◽

10.1186/s13063-017-2275-y ◽

2017 ◽

Vol 18 (1) ◽

Cited By ~ 7

Author(s):

Inti Qurashi ◽

Imran B. Chaudhry ◽

Ameer B. Khoso ◽

Sana Farooque ◽

Steve Lane ◽

...

Keyword(s):

Fatty Acids ◽

Study Protocol ◽

Controlled Trial ◽

Mental States ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Double Blind ◽

Treatment As Usual ◽

Double Blind Placebo ◽

At Risk Mental States

Download Full-text

Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: A double-blind placebo-controlled trial followed by an open-label extension

European Psychiatry ◽

10.1016/j.eurpsy.2012.11.001 ◽

2013 ◽

Vol 28 (6) ◽

pp. 386-391 ◽

Cited By ~ 5

Author(s):

I. Manor ◽

A. Magen ◽

D. Keidar ◽

S. Rosen ◽

H. Tasker ◽

...

Keyword(s):

Fatty Acids ◽

Rating Scale ◽

Controlled Trial ◽

Study Groups ◽

Open Label ◽

Double Blind ◽

Blood Biochemical ◽

Study Results ◽

Open Label Extension ◽

Safety Parameters

AbstractObjective:To evaluate the safety of phosphatidylserine (PS) enriched with omega3 fatty acids, mainly eicosapentaenoic (PS-Omega3) in children with attention-deficit hyperactivity disorder (ADHD).Methods:Two hundred children diagnosed with ADHD were randomised to receive either PS-Omega3 (300 mg PS-Omega3/day) or placebo for 15 weeks. One hundred and fifty children continued into an open-label extension for an additional 15 weeks in which they all consumed PS-Omega3 (150 mg PS-Omega3/day). Standard blood biochemical and haematological safety parameters, blood pressure, heart rate, weight and height were evaluated. Adverse events and the Side Effect Rating Scale were also assessed.Results:One hundred and sixty-two participants completed the double-blind phase. No significant differences were noted between the two study groups in any of the safety parameters evaluated. One hundred and forty participants completed the open-label phase. At the end of this phase, no significant changes from baseline were observed in any of the studied parameters among participants who consumed PS-Omega3 for 30 weeks.Conclusions:Study results demonstrate that consumption of PS-Omega3 by children with ADHD, as indicated in a 30-week evaluation period, is safe and well tolerated, without any negative effect on body weight or growth.

Download Full-text